UAE Cardiovascular Drugs Market Analysis Report 2022 to 2030

UAE Cardiovascular Drugs Market Analysis

$ 3999

UAE Cardiovascular Drug Market is at around $0.67 Bn in 2022 and is projected to reach $1.01 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period. Major reasons propelling the growth of this market are technological advancements, health insurance coverage, and partnerships with other pharmaceutical industries. The market is dominated by key players like Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.

ID: IN10AEPH007 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Aneri Parekh

Buy Now

UAE Cardiovascular Drug Market Executive Summary

UAE Cardiovascular Drug Market is at around $0.67 Bn in 2022 and is projected to reach $1.01 Bn in 2030, exhibiting a CAGR of 4.8% during the forecast period.

Heart and blood vessel illnesses are collectively referred to as cardiovascular diseases. These comprise deep vein thrombosis, pulmonary embolism, congenital heart disease, peripheral artery disease, rheumatic heart disease, and coronary heart disease. Angiotensin-II antagonists (like losartan), antiarrhythmics (like amiodarone), and ACE inhibitors (like ramipril) are the three main classes of medications used to treat heart-related issues.

The market for cardiovascular drugs in the United Arab Emirates is anticipated to be impacted by various factors, including the aging population, changes in lifestyle, and the prevalence of cardiovascular illnesses. A variety of drugs are available in the market to treat problems such as high blood pressure, high cholesterol, heart failure, arrhythmias, and blood clot prevention. The market environment may also be shaped by government programs to improve cardiovascular health, healthcare infrastructure, and regulatory laws. The dynamics of the market may also be impacted by variables including patient awareness, healthcare spending, and the accessibility of new and generic medications.

The pharmaceutical industry is responsible for drug discovery, production, distribution, and research. Over the previous two decades, pharmaceutical revenues rose rapidly, reaching $138.33 Bn worldwide in 2022. The pharmaceutical sector has experienced a dramatic shift with the advent of new technology and more affordable and efficient manufacturing methods. Furthermore, the increasing flow of capital into this industry has helped the market to flourish.

In the UAE, F. Hoffmann-La Roche is a significant player in the cardiovascular medicine industry. Their strong presence across multiple pharmacological segments, especially antihypertensives and anticoagulants, accounts for their dominant position. Well-known brands like the antiplatelet drug Plavix and the medication Avastin, which is utilized in various cardiovascular procedures, contribute to this success.

UAE cardiovascular drug market

Market Dynamics

Market Growth Drivers:

Technological Developments: The creation of new and more potent heart medications may result from developments in medical research and technology, driving the expansion of the market.

Health Insurance Coverage: The availability of health insurance coverage has a favorable effect on the market for cardiovascular medications by making vital drugs and treatments affordable for people.

Global Coordination and Partnerships: New cardiovascular medications may be introduced to the UAE market through partnerships between foreign pharmaceutical corporations and regional healthcare facilities or governmental organizations.

Market Restraints:

Economic Factors: Uncertainties or downturns in the economy may affect healthcare spending and may result in a decline in the market for pharmaceutical items, such as heart medication.

Emergence of Alternatives: The traditional pharmaceutical market may be impacted by developments of non-pharmacological interventions or innovative therapies as alternatives to existing treatment options.

Global Health Crisis: Pandemics and other global health crises have the potential to upset supply chains, damage the healthcare system, and change patient behavior, all of which can have an effect on the market for cardiovascular medications.

Healthcare Policies and Regulatory Landscape

In the United Arab Emirates (UAE) the Ministry of Health and Prevention (MoHAP) is in charge of regulating pharmaceuticals. The procedure is filing the request online via the MoHAP website, fulfilling all requirements, paying the necessary costs, and then sending the report to the relevant ministerial committee. Adherence to Good Manufacturing Practices (GMP) is crucial in obtaining medicine approval. Strict quality standards must be followed by the manufacturing facilities making the pharmaceuticals to guarantee the consistency and quality of the products, which could complicate the procedure.

Competitive Landscape

Key Players:

Bristol-Myers Squibb Company
Pfizer Inc.
Bayer AG
Janssen Pharmaceuticals, Inc.
AstraZeneca
Sanofi
Novartis AG
Merck & Co., Inc.
Gilead Sciences, Inc.
F. Hoffmann-La Roche Ltd

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Cardiovascular Drug Market Segmentation

By Drug Type

Cephalosporins
Antihypertensive
Antihyperlipidemic
Anticoagulants
Antiplatelet Drug
Other

By Disease Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Arrhythmia
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.